secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2026-09-03T20:12:25+00:00
Accession:  0001193125-26-381899
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva reports $500M duvakitug milestone, $2.2B debt issuance, and $29.6B goodwill impairment
--------------------------------------------------------------------------------

- $500M milestone received in Q4 2025 for duvakitug Phase 3 initiation; $500M upfront in Q4 2023.
- Issued $700M 5.75% notes due 2030, €1B 4.125% due 2031, $500M 6.00% due 2032 in May 2025.
- Tender offer extinguished $1.579B of 3.15% notes due 2026 and other notes; $10M loss recorded.
- Cumulative goodwill impairment stable at $29.6B as of Dec 31, 2025 and 2024.
- Repaid $1.812B of senior notes maturing in 2025 during the year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/0001193125-26-381899-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-381899

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer